ADHD drugs 'made 30 children suicidal'
October 13, 2009
The number of serious reactions to ADHD drugs has doubled in a three-year period, according to Therapeutic Goods Administration figures published by News Ltd.
Acting opposition health spokesman Mathias Cormann says Health Minister Nicola Roxon has sat on her hands for almost two years.
His comments follow reports 30 children have wanted to kill themselves while on drugs for attention deficit hyperactivity disorder (ADHD).
Attention Deficit Hyperactivity Disorder in Children Referencesthat may prove usefull.
1. Froehlich TE, Lanphear BP, Epstein JN, Barbaresi WJ, Katusic SK, Kahn RS. Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children. Arch Pediatr Adolesc Med. 2007; 161(9): 857-64.
2. National Institute of Mental Health (NIMH). Attention deficit hyperactivity disorder (ADHD), NIH Publication No 3572 [online]. National Institutes of Health. 3 April 2008 [cited 24 December 2008]. Available from URL: http://www.nimh.nih.gov/
health/ publications/ adhd/ complete-publication.shtml
3. The Royal Australasian College of Physicians, Paediatrics & Child Health Division. Medication management for attention deficit hyperactivity disorder: A brief guide for parents and non health professionals [online]. 10 July 2006 [cited 24 December 2008]. Available from URL: http://www.racp.edu.au/
4. Scottish Intercollegiate Guidelines Network. Attention deficit and hyperkinetic disorders in children and young people: A national clinical guidline [online]. 29 June 2001 [cited 24 December 2008]. Available from URL: http://www.sign.ac.uk/
5. NSW Health pharmaceutical Services Branch. Criteria for diagnosis and management of attention deficit hyperactivity disorder in children and adolescents [online]. NSW Health. 1 February 2008 [cited 24 December 2008]. Available from URL: http://www.health.nsw.gov.au/
resources/ publichealth/ pharmaceutical/ adhd_criteria_child.asp
6. Polanczyk G,de Lima MS,Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psych. 2007; 164(6): 942-8.
7. Sawyer MG, Kosky RJ, Graetz BW, Arney F, Zubrick SR, Baghurst P. The National Survey of Mental Health and Wellbeing: The child and adolescent component. Aust NZ J Psych. 2000; 34(2): 214-20.
8. Clinical Excellence Commission. Attention deficit hyperactivity disorder in children and adults in New South Wales 2007: Final report of the special review [online]. 2 May 2008 [cited 24 December 2008]. Available from URL: http://www.cec.health.nsw.gov.au/
pdf/ specialreports/ adhd_080211.pdf
9. Buckmaster L. Research brief no. 2 200405: Medication for attention/deficit hyperactivity disorder (ADHD): An analysis by Federal Electorate (200103). Australian Parliamentary Library. 16 November 2004. [cited 21 September 2009]. Available from URL: http://www.aph.gov.au/
library/ pubs/ RB/ 2004-05/ 05rb02.htm
10. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, et al. Molecular genetics of attention deficit/hyperactivity disorder. Biol Psychiatry. 2005; 57(11): 1313-23.
11. Wallis D, Russell HF, Muenke M. Review: Genetics of attention deficit/hyperactivity disorder. J Pediatr Psychol. 2008; 33(10): 1085-99.
12. Larsson H, Lichtenstein P, Larsson JO. Genetic contributions to the development of ADHD subtypes from childhood to adolescence. J Am Acad Child Adolesc Psychiatry. 2006; 45(8): 973-81.
13. Lowe N, Kirley A, Hawi Z, Sham P, Wickham H, Kratochvil CJ, et al. Joint analysis of the DRD5 marker concludes association with attention-deficit/hyperactivity disorder confined to the predominantly inattentive and combined subtypes. Am J Hum Genet. 2004; 74(2): 348-56.
14. Smalley SL, McCracken J, McGough J. Refining the ADHD phenotype using affected sibling pair families. Am J Med Genet. 2001; 105(1): 31-3.
15. Gerring JP, Brady KD, Chen A, Vasa R, Grados M, Bandeen-Roche KJ, et al. Premorbid prevalence of ADHD and development of secondary ADHD after closed head injury. J Am Acad Child Adolesc Psychiatry. 1998; 37(6): 647-54.
16. Sowell ER, Thompson PM, WelcomeSE, Henkenius AL, Toga AW, Peterson BS. Cortical abnormalities in children and adolescents with attention-deficit hyperactivity disorder. Lancet. 2003; 362: 1699-707.
17. Swain A, Soutter V, Loblay R, Truswell AS. Salicylates, oligoantigenic diets and behaviour. Lancet. 1985; 2: 41-2.
18. Konofal E, Lecendreux M, Arnulf I, Mouren M. Iron deficiency in children with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2004; 158(12): 1113-5.
19. Brown TE. Executive functions and attention deficit hyperactivity disorder: Implications of two conflicting views. Int J Disabil Develop Edu. 2006; 53(1): 35-46.
20. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007; 46(7): 894-921.
21. Faraone SV. Advances in the genetics and neurobiology of attention deficit hyperactivity disorder. Biol Psychiatry. 2006; 60(10):1025-7.
22. Kieling C, Goncalves RR, Tannock R, Castellanos FX. Neurobiology of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am. 2008; 17(2): 285-307, viii.
23. Burks HF. Burks' Behavior Rating Scale: Manual. Los Angeles: Western Psychological Services; 1996.
24. Conners CK, Sitarenios G, Parker JDA, Epstein JN. The revised Conner's Parent Rating Scale (CPRS-R): Factor structure, reliability and criterion validity. J Abnorm Child Psych. 1998; 26(4): 257-68.
25. Lubar JF, Swartwood MO, Swartwood JN, O'Donnell PH. Evaluation of the effectiveness of EEG neurofeedback training for ADHD in a clinical setting as measured by changes in T.O.V.A. scores, behavioral ratings, and WISC-R performance. Appl Psychophysiol Biofeedback. 1995; 20(1): 83-99.